-
公开(公告)号：US10709706B2
公开(公告)日：2020-07-14
申请号：US16066572
申请日：2016-12-30
发明人： Erkan Baloglu
IPC分类号： A61K31/506 , C07D241/12 , C07D403/06 , C07D403/08 , C07D401/08 , C07D403/12 , C07D239/26 , C07D413/06 , C07D401/12 , C07D409/06 , A61P35/00
摘要： The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
-
公开(公告)号：US10519139B2
公开(公告)日：2019-12-31
申请号：US15503319
申请日：2015-08-14
发明人： Brian C. Austad , David G. Roe
IPC分类号： C07D403/12 , A61P35/00
摘要： The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.
-
公开(公告)号：US20170319551A1
公开(公告)日：2017-11-09
申请号：US15413889
申请日：2017-01-24
IPC分类号： A61K31/4196 , C07D403/12 , C07D401/12 , C07D249/08 , A61K31/454 , A61K45/06 , A61K31/5377 , A61K31/497 , C07D413/12 , C07D401/10
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
-
公开(公告)号：US09585874B2
公开(公告)日：2017-03-07
申请号：US14989377
申请日：2016-01-06
IPC分类号： A61K31/5377 , A61K31/4196 , A61K31/454 , A61K31/497 , C07D249/08 , C07D403/12 , C07D401/12 , C07D413/12
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，包含式I化合物的药物组合物，以及使用所述化合物，盐和组合物治疗与CRM1活性相关的各种疾病的方法。
-
公开(公告)号：US09550757B2
公开(公告)日：2017-01-24
申请号：US13931372
申请日：2013-06-28
IPC分类号： A61K31/4196 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/505 , C07D409/04 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12
CPC分类号： C07D409/04 , A61K31/4196 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/505 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
公开(公告)号：US20160354347A1
公开(公告)日：2016-12-08
申请号：US14989377
申请日：2016-01-06
IPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
摘要翻译： 其药学上可接受的盐，包含式I化合物的药物组合物，以及在治疗与CRM1活性相关的各种疾病中使用所述化合物，盐和组合物的方法。
-
公开(公告)号：US20160221994A1
公开(公告)日：2016-08-04
申请号：US14647662
申请日：2013-11-27
发明人： Erkan Baloglu , Sharon Shechter , Sharon Shacham , Dilara McCauley , William Senapedis , Gali Golan , Ori Kalid
IPC分类号： C07D405/12 , C07D413/14 , C07D495/04 , C07D409/12 , C07D417/14 , C07D409/14 , C07D409/04
CPC分类号： C07D405/12 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/14 , C07D495/04
摘要： The invention generally relates to substituted 2,3-dihydrobenzofuranyl compounds, and more particularly to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.
摘要翻译： 本发明一般涉及取代的2,3-二氢苯并呋喃基化合物，特别是涉及由结构式（I）表示的化合物或其药学上可接受的盐，其中变量如本文所定义和描述。 本发明还包括结构式（I）的化合物或其药学上可接受的盐或组合物的合成和用途，例如用于治疗癌症（例如，套细胞淋巴瘤）和其它疾病和病症。
-
公开(公告)号：US09266843B2
公开(公告)日：2016-02-23
申请号：US14399868
申请日：2013-05-09
IPC分类号： A61K31/5377 , A61K31/4196 , A61K31/454 , A61K31/497 , C07D249/08 , C07D403/12 , C07D401/12 , C07D413/12 , A61K45/06
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，包含式I化合物的药物组合物，以及使用化合物，盐和组合物治疗与CRM1活性相关的各种疾病的方法。
-
公开(公告)号：US09096543B2
公开(公告)日：2015-08-04
申请号：US13891044
申请日：2013-05-09
IPC分类号： A61K31/5377 , C07D413/12 , C07D401/12 , C07D249/08 , C07D403/12 , A61K31/4196 , A61K31/454 , A61K31/497 , A61K45/06
CPC分类号： A61K31/4196 , A61K31/454 , A61K31/497 , A61K31/5377 , A61K45/06 , C07D249/08 , C07D401/10 , C07D401/12 , C07D403/12 , C07D413/12 , Y02A50/465
摘要： The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐，包含式I化合物的药物组合物，以及使用所述化合物，盐和组合物治疗与CRM1活性相关的各种疾病的方法。
-
公开(公告)号：US20140155370A1
公开(公告)日：2014-06-05
申请号：US13931372
申请日：2013-06-28
IPC分类号： C07D417/12 , C07D405/12 , C07D401/12 , C07D403/04 , C07D401/04 , C07D403/12 , C07D417/04 , C07D401/14 , C07D249/08 , C07D409/04
CPC分类号： C07D409/04 , A61K31/4196 , A61K31/433 , A61K31/4439 , A61K31/444 , A61K31/496 , A61K31/505 , C07D207/337 , C07D231/12 , C07D233/64 , C07D249/08 , C07D257/04 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12
摘要： The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
摘要翻译： 本发明一般涉及核转运调节剂领域，例如CRM1抑制剂，更具体地涉及新的取代杂环唑化合物，这些化合物及其药物组合物的合成和用途，例如在治疗，调节和/或 预防与CRM1活性相关的生理条件，例如治疗癌症和其它肿瘤性疾病，炎症性疾病，异常组织生长障碍和纤维化，包括心肌病，肺纤维化，肝纤维化，肾小球性肾炎和其他肾脏疾病，以及用于治疗病毒 感染（急性和慢性）。
-
-
-
-
-
-
-
-
-
搜索结果
68 条记录 (耗时 0.061 秒)